Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia-Long-term results of trial ALL-REZ BFM P95/96

European Journal of Cancer

Volumn 49, Issue 6, 2013, Pages 1346-1355

  Eckert, Cornelia ^a   Von Stackelberg, Arend ^a   Seeger, Karl ^a   Groeneveld, Tom W L ^a   Peters, Christina ^b   Klingebiel, Thomas ^c   Borkhardt, Arndt ^d   Schrappe, Martin ^e   Escherich, Gabriele ^f   Henze, Günter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d Department of Orthopedic Surgery   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Acute lymphoblastic leukaemia; Childhood; Intermediate risk; MRD; Prognosis; Relapse; Stratification

Indexed keywords

ASPARAGINASE MACROGOL; CYTARABINE; DEXAMETHASONE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CHILD; EVENT FREE SURVIVAL; FEMALE; FUSION GENE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS; INDUCTION CHEMOTHERAPY; MALE; NEOPLASM, RESIDUAL; OUTCOME ASSESSMENT (HEALTH CARE); PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; RISK ASSESSMENT; RISK FACTORS;

EID: 84875721185     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.11.010     Document Type: Article

References (37)

1. L.C. Bailey, B.J. Lange, and S.R. Rheingold Bone-marrow relapse in paediatric acute lymphoblastic leukaemia Lancet Oncol 9 2008 873 883
2. P.S. Gaynon Childhood acute lymphoblastic leukaemia and relapse Br J Haematol 131 2005 579 587
3. G. Henze, and A. vonStackelberg Treatment of relapsed acute lymphoblastic leukemia C.H. Pui, Treatment of acute leukemias. New directions for clinical research 2002 Humana Press
4. C. Buhrer, R. Hartmann, and R. Fengler Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia Med Pediatr Oncol 21 1993 470 476
5. G. Henze, R. Fengler, and R. Hartmann Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group Blood 78 1991 1166 1172
6. G. Tallen, R. Ratei, and G. Mann Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90 J Clin Oncol 28 2010 2339 2347
7. S.E. Lawson, G. Harrison, and S. Richards The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study Br J Haematol 108 2000 531 543
8. D. Pinkel 'Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone': twenty years later Leukemia 23 2009 2189 2196
9. G. Basso, M. Veltroni, and M.G. Valsecchi Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow J Clin Oncol 27 2009 5168 5174
10. M.J. Borowitz, M. Devidas, and S.P. Hunger Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study Blood 111 2008 5477 5485
11. H. Cave, J. Van der Werff ten Bosch, and S. Suciu Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group N Engl J Med 339 1998 591 598
12. V. Conter, C.R. Bartram, and M.G. Valsecchi Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood 115 2010 3206 3214
13. E. Coustan-Smith, J. Sancho, and F.G. Behm Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia Blood 100 2002 52 58
14. M.N. Dworzak, G. Froschl, and D. Printz Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia Blood 99 2002 1952 1958
15. J.J. van Dongen, T. Seriu, and E.R. Panzer-Grumayer Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 352 1998 1731 1738
16. C. Eckert, A. Biondi, and K. Seeger Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia Lancet 358 2001 1239 1241
17. E. Coustan-Smith, A. Gajjar, and N. Hijiya Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse Leukemia 18 2004 499 504
18. E.A. Raetz, M.J. Borowitz, and M. Devidas Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a Children's Oncology Group Study J Clin Oncol 26 2008 3971 3978
19. A. Borgmann, A. von Stackelberg, and R. Hartmann Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis Blood 101 2003 3835 3839
20. B. Reismuller, A. Attarbaschi, and C. Peters Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria-a population-based report of the Austrian Berlin-Frankfurt-Munster (BFM) Study Group Br J Haematol 144 2009 559 570
21. C. Buhrer, R. Hartmann, and R. Fengler Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Munster Relapse Study Group J Clin Oncol 14 1996 2812 2817
22. A.W. Langerak, T. Szczepanski, and M. van der Burg Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations Leukemia 11 1997 2192 2199
23. M.J. Pongers-Willemse, T. Seriu, and F. Stolz Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia Leukemia 13 1999 110 118
24. T. Szczepanski, M.J. Pongers-Willemse, and A.W. Langerak Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage Blood 93 1999 4079 4085
25. T. Szczepanski, V.H. van der Velden, and P.G. Hoogeveen Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells Blood 103 2004 3798 3804
26. J.J. van Dongen, and I.L. Wolvers-Tettero Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders Clin Chim Acta 198 1991 93 174
27. J.J. van Dongen, and I.L. Wolvers-Tettero Analysis of immunoglobulin and T cell receptor genes. Part I: basic and technical aspects Clin Chim Acta 198 1991 1 91
28. C. Eckert, and O. Landt Real-time PCR to detect minimal residual disease in childhood ALL Methods Mol Med 91 2004 175 182
29. C. Eckert, C.A. Scrideli, and T. Taube Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes Leukemia 17 2003 2517 2524
30. V.H. van der Velden, G. Cazzaniga, and A. Schrauder Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data Leukemia 21 2007 604 611
31. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
32. J.D. Kalbfleisch, and R.L. Prentice The statistical analysis of failure time data 1980 Wiley New York 168-89
33. S.J. Pocock, T.C. Clayton, and D.G. Altman Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls Lancet 359 2002 1686 1689
34. C. Clayton, and M. Hills Statistical models in epidemiology 2005 Oxford Scientific Publications
35. D. Bhojwani, D. Pei, and J.T. Sandlund ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy Leukemia 26 2011 265 270
36. D. Hoelzer, N. Gokbuget, and O. Ottmann Acute lymphoblastic leukemia Hematol Am Soc Hematol Educ Program 2002 162 192
37. U. zur Stadt, D.O. Harms, and S. Schluter MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen Leukemia 15 2001 283 285